References
- Fuchs TC, Hewitt P. Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity what we know and what we need to know. Biomark Med. 2011;5:763–779.
- Loghman-Adham M, Weber CIK, Ciorciaro C, et al. Detection and management of nephrotoxicity during drug development. Expert Opin Drug Saf. 2012;11:581–596.
- Hamdam J, Sethu S, Smith T, et al. Safety pharmacology–current and emerging concepts. Toxicol App Pharmacol. 2013;273:229–241.
- Xie HG, Wang SK, Cao CC, et al. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacol Ther. 2013;137:100–107.
- Lombi F, Muryan A, Canzonieri R, et al. Biomarkers in acute kidney injury: evidence or paradigm. Nefrologia. 2016;36:339–346.
- Ostermann M, Phillips BJ, Forni LG. Clinical review: biomarkers of acute kidney injury: where are we now? Crit Care. 2012;16:233.
- Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol. 2015;10:147–155.
- Liu X, Guan Y, Xu S, et al. Early predictors of acute kidney injury: a narrative review. Kidney Blood Press Res. 2016;41:680–700.
- McCaffrey J, Dhakal AK, Milford DV, et al. Recent developments in the detection and management of acute kidney injury. Arch Dis Child. 2017;102:91–96.
- Rizvi MS, Kashani KB. Biomarkers for early detection of acute kidney injury. J Appl Lab Med. 2017;2:386–399.
- National Center for Biotechnology Information. National library of medicine. BEST (Biomarkers, EndpointS, and other Tools) Resource. [cited 2018 Jul 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_NBK326791.pdf
- Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics. 2001;69:89–95.
- U. S. Food and Drug Administration. For patients. learn about drug and device approvals. fast track, breakthrough therapy, accelerated approval and priority review. Accelerated Approval. [cited 2018 Jul 12]. Available from: https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm
- Food US, Administration D. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Mar 2004. [cited 2018 Jul 12]. Available from: http://wayback.archive-it.org/7993/20180125035500/https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf
- Food US, Administration D. Advancing regulatory science for public health. a framework for fda’s regulatory science initiative. Oct 2010. [cited 2018 Jul 12]. Available from: https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM228444.pdf.
- Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.
- Mahajan R, Gupta K. Food and drug administration’s critical path initiative and innovations in drug development paradigm: challenges, progress, and controversies. J Pharm Bioallied Sci. 2010;2(4):307–313.
- Parekh A, Buckman-Garner S, McCune S, et al. Catalyzing the Critical Path Initiative: FDA’s progress in drug development activities. Clin Pharmacol Ther. 2015;97:221–233.
- Wholley D. The biomarkers consortium. Nat Rev Drug Discov. 2014;13:791–792.
- Mattes WB, Walker EG, Abadie E, et al. Research at the interface of industry, academia and regulatory science. Nat Biotechnol. 2010;28:432–433.
- Goldman M, Compton C, Mittleman BB. Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med. 2013;2:2.
- Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007;9:E105E108.
- Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Biotechnol. 2010;28:455–462.
- Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Accelerating the development of biomarkers for drug safety: workshop summary. Washington (DC): National Academies Press (US); 2009. 4, Assessing and Predicting Kidney Safety. [cited 2018 Jul 12] Available from: https://www.ncbi.nlm.nih.gov/books/NBK32719/[Last].
- Lin Z, Will Y. Evaluation of drugs with specific organ toxicities in organ-specificcell lines. Toxicol Sci. 2012;126:114–127.
- Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011;23:194–200.
- Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant. 2009;24:3263–3265.
- Goodsaid F, Papaluca M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol. 2010;28:441–443.
- Warnock DG, Peck CC. A roadmap for biomarker qualification. Nat Biotechnol. 2010;28:444–445.
- U. S. Food and Drug Administration. Drug development tools qualification programs. Biomarker qualification program. List of Qualified Biomarkers. [cited 2018 Jul 12]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535383.htm.
- U. S. Food and Drug Administration. Drug development tools qualification programs. Biomarker qualification program. Current Biomarker Qualification Submissions. [cited 2017 Oct 19]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535881.htm.
- Biomarker Assay Collaborative Evidentiary Considerations Writing Group. Scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. [cited 2018 Jul 12] Available from: https://healthpolicy.duke.edu/sites/default/files/atoms/files/cpath_ptc_biomarker_qualification_assays_20170623.pdf
- U. S. Food and Drug Administration. Biomarker Qualification Program. Biomarker Guidances and Reference Materials. [cited 2018 Jul 12]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm536018.htm.
- Amur SG, Sanyal S, Chakravarty AG, et al. Building a roadmap to biomarker qualification: challenges and opportunities. Biomark Med. 2015;9:1095–1105.
- Amur S, LaVange L, Zineh I, et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Therap. 2015;98:34–46.
- Leptak C, Menetski MP, Wagner JA, et al. What evidence do we need for biomarker qualification? Sci Transl Med. 2017;9:eaal4599.
- U. S. Food and Drug Administration. Drug development tools qualification programs. Biomarker Qualification Program. [cited 2018 Jul 12] Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/default.htm
- Sauer JM, Porter AC. Biomarker programs, predictive safety testing consortium. Preclinical biomarker qualification. Exp Biol Med (Maywood). 2017. DOI:10.1177/1535370217743949
- SAFE-T Consortium. Summary data package, novel clinical biomarkers of drug-induced kidney injury, the drug-induced kidney injury work package of innovative medicines. [cited 2018 Jul 12]. Available from: http://www.imi-safe-t.eu/files/files-inline/DIKI_data_summary_final_20170925.pdf
- United States Congress. Bills. 21st Century Cures Act. [cited 2018 Jul 12] Available from: https://www.congress.gov/114/bills/hr34/BILLS-114hr34enr.pdf
- U. S. Food and Drug Administration. Drug development tools qualification programs. Biomarker Qualification Program. [cited 2018 Jul 12]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm
- Wang K, Huang CH, Nice EC. Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers. Expert Rev Proteomics. 2014;11:179–205.
- Geyer PE, Holdt LM, Teupser D, et al. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13:942.
- Liang Q, Liu H, Xie L, et al. High-throughput metabolomics enables biomarker discovery in prostate cancer. RSC Adv. 2017;7:2587.
- Antoranz A, Sakellaropoulos T, Saez-Rodriguez J, et al. Mechanism-based biomarker discovery. Drug Disc Today. 2017;22:1209–1215.
- Murray PT, Mehta RL, Shaw A, et al. ADQI 10 workgroup. 2014. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th acute dialysis quality initiative consensus conference. Kidney Int. 2014;85:513–521.
- Arthur JM, Hill EG, Alge JL, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. Kidney Int. 2014;85:431–438.
- Lieske JC, Lakhmir C, Kashani K, et al. Biomarkers for acute kidney injury: where are we today? Where should we go? Clin Chem. 2014;60:294–300.
- Malyszko J, Lukaszyk E, Glowinska I, et al. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Nat Scien Reports. 2015;5:11684.
- Parikh CR, Moledina DG, Sg C, et al. Application of new kidney injury biomarkers in human randomized controlled trials. Kidney Int. 2016;89:1372–1379.
- Peng Z-Y. The biomarkers for acute kidney injury: a clear road ahead? J Transl Int Med. 2016;4:95–98.